Skip to contentG
GT Biopharma, Inc.
G
GTBPGT Biopharma, Inc. Q3 2013 · 10-Q
Revenue$183.00K$183.00K+52.5% vs Q3 2012 Net Income-$319.00K-$319.00KN/M vs Q3 2012 EPS Diluted$0.00$0.00— vs Q3 2012 Gross Profit$60,000−31.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
Operating Cash Flowderived$45,000N/M Margins · derivedGross margin32.8%−40.5 pt vs Q3 2012
Operating margin-76.5%+1048.5 pt vs Q3 2012
Net margin-174.3%+992.3 pt vs Q3 2012
ended Sep 30, 2013 · filed Dec 17, 2014 · 443 d after period end